In this regard, serum levels of interleukins such as IL-6 and IL-8, associated with a high risk of IPA, could play a role as possible predictive biomarkers for higher risk of CAPA and thus be included in therapeutic decision-making [78,79]. The gene discussed is IL6; the disease is episodic ataxia type 2.